BACKGROUND: The neurofilament light chain (NfL) in cerebrospinal fluid (CSF) and serum as a marker of neuronal damage may be a potential biomarker of neuropsychiatric involvement in SLE (NPSLE). METHODS: 80 patients with SLE were included.We obtained paired serum and CSF samples from 48 patients (NPSLE n=32, non-NPSLE n=16) and 31 controls. The serum and CSF levels of NfL were determined using ELISA. RESULTS: Patients with NPSLE demonstrated significantly higher levels of serum NfL compared with the non-NPSLE group (mean 31.68±36.63 pg/mL vs mean 16.75±12.48 pg/mL, respectively, p<0.05) and with controls (mean 10.74±4.36 pg/mL, p<0.01). Notably, CSF NfL concentrations in patients with NPSLE showed an upward trend (mean 1600±2852 pg/mL) in contrast to non-NPSLE patients (mean 393.4±191.9 pg/mL) and controls (mean 509.7±358.5 pg/mL). Furthermore, a positive correlation was observed between serum and CSF NfL levels in patients with NPSLE (R=0.8686, p<0.01). Elevated serum triacylglycerol concentrations, C reactive protein and organ damage were linked to increased serum (p=0.002; p<0.001; p=0.036) and CSF (p=0.008; p=0.007; p<0.001) NfL concentrations. In addition, we established a significant correlation between intrathecal NfL concentrations and interleukin-6 levels in the CSF of patients with NPSLE (R=0.5118, p<0.05). CONCLUSION: The serum NfL levels may be a readily available marker of neuropsychiatric involvement in SLE.

Department of Neurology Charles University Prague Czech Republic

Department of Rheumatology Charles University Praha Czech Republic

Institute of Rheumatology Prague 2 Czech Republic

Zobrazit více v PubMed

Unterman A, Nolte JES, Boaz M, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41:1–11. doi: 10.1016/j.semarthrit.2010.08.001. PubMed DOI

Bortoluzzi A, Scirè CA, Bombardieri S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatol (Sunnyvale) 2015;54:891–8. doi: 10.1093/rheumatology/keu384. PubMed DOI

Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338–47. doi: 10.1038/nrrheum.2014.15. PubMed DOI

Sibbitt WL, Jr, Brandt JR, Johnson CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol. 2002;29:1536–42. PubMed

Govoni M, Bortoluzzi A, Padovan M, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun. 2016;74:41–72. doi: 10.1016/j.jaut.2016.06.013. PubMed DOI

Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010;6:358–67. doi: 10.1038/nrrheum.2010.62. PubMed DOI

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608. doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F. PubMed DOI

Lindblom J, Mohan C, Parodis I. Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade. Brain Sci. 2022;12:192. doi: 10.3390/brainsci12020192. PubMed DOI PMC

Balajkova V, Olejarova M, Moravcova R, et al. Is serum TWEAK a useful biomarker of neuropsychiatric systemic lupus erythematosus? Physiol Res. 2020;69:339–46. doi: 10.33549/physiolres.934308. PubMed DOI PMC

Yuan A, Rao MV, Nixon RA, et al. Neurofilaments and Neurofilament Proteins in Health and Disease. Cold Spring Harb Perspect Biol. 2017;9:a018309. doi: 10.1101/cshperspect.a018309. PubMed DOI PMC

Alirezaei Z, Pourhanifeh MH, Borran S, et al. Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders. Mol Neurobiol. 2020;57:469–91. doi: 10.1007/s12035-019-01698-3. PubMed DOI PMC

Yuan A, Sershen H, Basavarajappa BS, et al. Neurofilament subunits are integral components of synapses and modulate neurotransmission and behavior in vivo. Mol Psychiatry. 2015;20:986–94. doi: 10.1038/mp.2015.45. PubMed DOI PMC

Stone EJ, Kolb SJ, Brown A. A review and analysis of the clinical literature on Charcot-Marie-Tooth disease caused by mutations in neurofilament protein L. Cytoskeleton (Hoboken) -> Cyto (Hoboken) 2021;78:97–110. doi: 10.1002/cm.21676. PubMed DOI PMC

Sainio MT, Ylikallio E, Mäenpää L, et al. Absence of NEFL in patient-specific neurons in early-onset Charcot-Marie-Tooth neuropathy. Neurol Genet. 2018;4:e244. doi: 10.1212/NXG.0000000000000244. PubMed DOI PMC

Stone EJ, Uchida A, Brown A. Charcot-Marie-Tooth disease Type 2E/1F mutant neurofilament proteins assemble into neurofilaments. Cytoskeleton (Hoboken) -> Cyto (Hoboken) 2019;76:423–39. doi: 10.1002/cm.21566. PubMed DOI PMC

Sainio MT, Rasila T, Molchanova SM, et al. Neurofilament Light Regulates Axon Caliber, Synaptic Activity, and Organelle Trafficking in Cultured Human Motor Neurons. Front Cell Dev Biol. 2021;9:820105. doi: 10.3389/fcell.2021.820105. PubMed DOI PMC

Kouchaki E, Dashti F, Mirazimi SMA, et al. Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis. EXCLI J. 2021;20:1308–25. doi: 10.17179/excli2021-3973. PubMed DOI PMC

Robbins ML, Kornguth SE, Bell CL, et al. Antineurofilament antibody evaluation in neuropsychiatric systemic lupus erythematosus. Combination with anticardiolipin antibody assay and magnetic resonance imaging. Arthritis Rheum. 1988;31:623–31. doi: 10.1002/art.1780310507. PubMed DOI

Zmira O, Halpern AI, Drori T. Anti-neurofilament antibodies and neurodegeneration: Markers and generators. J Neuroimmunol. 2020;344:577248. doi: 10.1016/j.jneuroim.2020.577248. PubMed DOI

Engel S, Boedecker S, Marczynski P, et al. Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus. Ther Adv Neurol Disord. 2021;14:17562864211051497. doi: 10.1177/17562864211051497. PubMed DOI PMC

Tjensvoll AB, Lauvsnes MB, Zetterberg H, et al. Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren’s syndrome. J Neurol. 2021;268:1385–94. doi: 10.1007/s00415-020-10290-y. PubMed DOI PMC

Petri M, Orbai A-M, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–86. doi: 10.1002/art.34473. PubMed DOI PMC

Mosca M, Govoni M, Tomietto P, et al. The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice. Lupus (Los Angel) 2011;20:485–92. doi: 10.1177/0961203310389097. PubMed DOI

Balajkova V. Validation of a screening questionnaire for the presence of neuropsychiatric symptoms in patients with systemic lupus erythematosus in clinical practice. Česká revmatol. 2016;24:154–61.

Bortoluzzi A, Scirè CA, Bombardieri S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatol (Oxford) 2015;54:891–8. doi: 10.1093/rheumatology/keu384. PubMed DOI

Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288–91. PubMed

Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9. doi: 10.1002/art.1780390303. PubMed DOI

Team RC R: a language and environment for statistical computing. 2023

Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. JOSS . 2019;4:1686. doi: 10.21105/joss.01686. DOI

Lenth R. Estimated marginal means, aka least-squares means. R package version 1.4.7. 2020

Zervides KA, Janelidze S, Nystedt J, et al. Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus. BMC Neurol. 2022;22:467. doi: 10.1186/s12883-022-02998-3. PubMed DOI PMC

Lauvsnes MB, Zetterberg H, Blennow K, et al. Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus. J Neurol. 2022;269:3064–74. doi: 10.1007/s00415-021-10893-z. PubMed DOI

Trysberg E, Nylen K, Rosengren LE, et al. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003;48:2881–7. doi: 10.1002/art.11279. PubMed DOI

Morad CS, Mansour HE, Ahmed KA, et al. AB0481 Subclinical neuropsychiatric dysfunctions in systemic lupus erythematosus patients -a hospital based study. Annual European Congress of Rheumatology; 2017. DOI

Bortoluzzi A, Silvagni E, Furini F, et al. Peripheral nervous system involvement in systemic lupus erythematosus: a review of the evidence. Clin Exp Rheumatol. 2019;37:146–55. PubMed

Kawata K, Liu CY, Merkel SF, et al. Blood biomarkers for brain injury: What are we measuring? Neurosci Biobehav Rev. 2016;68:460–73. doi: 10.1016/j.neubiorev.2016.05.009. PubMed DOI PMC

Fialová L, Bartoš A, Švarcová J. Neurofilament light chains in serum and cerebrospinal fl uid and status of blood-CSF bar rier in the selected neurological diseases. Cesk Slov Neurol N . 2018;81/114:185–92. doi: 10.14735/amcsnn2018185. DOI

Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016;54:1655–61. doi: 10.1515/cclm-2015-1195. PubMed DOI

Feng M, Lv J, Fu S, et al. Clinical features and mortality in Chinese with lupus nephritis and neuropsychiatric lupus: A 124-patient study. J Res Med Sci . 2014;19:414–9. PubMed PMC

Khalil M, Pirpamer L, Hofer E, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. 2020;11:812. doi: 10.1038/s41467-020-14612-6. PubMed DOI PMC

Wilhelm AJ, Major AS. Accelerated atherosclerosis in SLE: mechanisms and prevention approaches. Int J Clin Rheumtol. 2012;7:527–39. doi: 10.2217/ijr.12.46. PubMed DOI PMC

Sol J, Jové M, Povedano M, et al. Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression. Brain Commun . 2021;3:fcab143. doi: 10.1093/braincomms/fcab143. PubMed DOI PMC

Hirohata S, Kikuchi H. Role of Serum IL-6 in Neuropsychiatric Systemic lupus Erythematosus. ACR Open Rheumatol. 2021;3:42–9. doi: 10.1002/acr2.11217. PubMed DOI PMC

Hirohata S, Sakuma Y, Yanagida T, et al. Association of cerebrospinal fluid anti-Sm antibodies with acute confusional state in systemic lupus erythematosus. Arthritis Res Ther . 2014;16:450. doi: 10.1186/s13075-014-0450-z. PubMed DOI PMC

Manca E. Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Can They Be Used as Biomarkers for the Differential Diagnosis of This Disease? Clinic Rev Allerg Immunol . 2022;63:194–209. doi: 10.1007/s12016-021-08865-2. PubMed DOI PMC

Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narváez A, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007;56:1242–50. doi: 10.1002/art.22451. PubMed DOI

Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 2016;1863:1218–27. doi: 10.1016/j.bbamcr.2016.03.018. PubMed DOI